DURVALUMAB + Datopotamab Deruxtecan for neoplasm metastasis

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 1 trial. Early trial in people, checking safety. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 5 Jul 2024: Trial started, NCT06508216
  2. 18 Jul 2024: Trial registered, NCT06508216

The trials

NCT06508216: A Study to Explore Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of Novel Therapeutics in Patients With Early Relapsed Metastatic Triple-negative Breast Cancer

State
Under way
Phase
Phase 1 and Phase 2
People
50 planned
Started
5 Jul 2024
Primary completion
17 Dec 2025
Arms
Module 2 of part 2 : Datopotamab Deruxtecan (Dato-DXd) + Durvalumab
Results
None posted
  1. 5 Jul 2024: Trial started
  2. 18 Jul 2024: Trial registered

How the status changed

  1. 19 Nov 2026: First set: Phase 1 trial

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.